A long-acting insulin analog formulated as a sterile solution for subcutaneous injection. It provides a steady, peakless insulin release over 24 hours to help control blood glucose in patients with diabetes mellitus.
Indications:
- Management of type 1 diabetes mellitus in adults and children ≥6 years.
- Management of type 2 diabetes mellitus in adults requiring long-acting insulin for glycemic control.
Main Active Ingredient:
- Insulin Glargine (100 IU/mL).
Precautions:
- Do not use in cases of known hypersensitivity to insulin glargine or any excipients.
- Not suitable for the treatment of diabetic ketoacidosis (use short-acting insulin instead).
- Monitor blood glucose levels regularly to avoid hypoglycemia or hyperglycemia.
- Caution in patients with renal or hepatic impairment (may require dose adjustment).
- Dose adjustments may be required during illness, stress, or changes in physical activity/diet.
- Keep out of reach of children.
Side Effects:
- Hypoglycemia.
- Injection site reactions (pain, redness, swelling, itching).
- Lipodystrophy at injection site.
- Allergic reactions including rash, urticaria, or anaphylaxis.
- Weight gain.
- Edema.
- Visual disturbances.
Drug-Drug Interactions:
- Increased risk of hypoglycemia with:
- Oral antidiabetic drugs.
- ACE inhibitors, angiotensin II receptor blockers.
- Beta-blockers, salicylates, fluoxetine, MAO inhibitors.
- Reduced effect (hyperglycemia risk) with:
- Corticosteroids.
- Thiazide diuretics.
- Sympathomimetics.
- Thyroid hormones.
- Masking of hypoglycemia symptoms: Beta-blockers, clonidine, guanethidine.
- Alcohol: may unpredictably increase or decrease insulin effect.
Insulin Glargine,Zinc chloride,Metacresol,Hydrochloric acid,Sodium hydroxide,Water for injections.